Table 3.

Association Between EQ‐5D VAS Score and Outcomes

Clinical Outcome	Unadjusted		Adjusted
	HR (95% CI)	P Value*	HR (95% CI)	P Value*
MACE†	0.92 (0.90–0.94)	<0.0001	0.96 (0.93–0.98)	0.0018
MALE‡	0.89 (0.85–0.93)	<0.0001	0.93 (0.88–0.98)	0.0088
ALI requiring hospitalization§	0.89 (0.84–0.95)	0.0002	0.91 (0.85–0.98)	0.0070
Major amputation‖	0.88 (0.83–0.93)	<0.0001	0.93 (0.86–1.00)	0.0535
LER¶	0.95 (0.93–0.97)	<0.0001	0.94 (0.92–0.96)	<0.0001

ALI indicates acute limb ischemia; HR, hazard ratio; LER, lower‐extremity revascularization; MACE, major adverse cardiovascular event; MALE, major adverse limb event; and VAS, visual analog scale.

^*We used a Cox proportional hazards model, landmarked at 12 months and controlled for the baseline scores in all unadjusted and adjusted models.

^†Adjusted for Rutherford score, sex, inclusion criteria, region, prior stroke, prior carotid revascularization, prior myocardial infarction (MI), prior percutaneous coronary intervention (PCI), diabetes mellitus, statin use, tobacco use, prior minor amputation, age, ankle–brachial index (ABI), weight, estimated glomerular filtration rate (eGFR), ticagrelor (study arm).

^‡Adjusted for Rutherford score, sex, inclusion criteria, prior carotid revascularization, prior carotid stenosis, diabetes mellitus, angiotensin II receptor blocker (ARB) use, prior minor amputation, prior major amputation, statin use and ABI, ticagrelor (study arm).

^§Adjusted for inclusion criteria, ABI, hypertension, prior carotid revascularization, ARB use, ticagrelor (study arm).

^‖Adjusted for Rutherford score, inclusion criteria, prior carotid stenosis, prior carotid revascularization, diabetes mellitus, statin use, prior major amputation, prior minor amputation, ABI, weight, ticagrelor (study arm).

^¶Adjusted for inclusion criteria, region, ABI, tobacco use, diabetes mellitus, prior clopidogrel use, prior aspirin use, ticagrelor (study arm).